Back
Compare AU
Compare DRUG vs. DACE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Dimensional Australian Core Equity Trust - Active ETF (DACE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | DACE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 73 | 19 |
Median incremental investment | $740.50 | $2,446.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,623.50 | $6,032.04 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | DACE | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | DACE.AX was created on 2006-07-03 by Dimensional. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to provide long-term capital growth by gaining exposure to a diversified portfolio of securities listed in Australia with increased emphasis on higher expected return securities relative to a Market Capitalisation Weighted portfolio |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | BHP Group Ltd (9.04 %) Commonwealth Bank of Australia (3.94 %) Westpac Banking Corp (2.86 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Financials (40.36 %) Materials (26.23 %) Consumer Discretionary (7.34 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | Australia (99.58 %) United States (0.39 %) New Zealand (0.02 %) |
Management fee | 0.57 % | 0.28 % |
Key Summary
DRUG | DACE | |
|---|---|---|
Issuer | BetaShares | Dimensional |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P/ASX 300 Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.28 % |
Price | $8.50 | $18.06 |
Size | $176.672 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 2.57 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 12/11/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | DACE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 73 | 19 |
Median incremental investment | $740.50 | $2,446.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,623.50 | $6,032.04 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | DACE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | DACE |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |